Both medicines are started on a low dose and increased to a maintenance dose of 2.4 mg for Wegovy and 3 mg for Saxenda
Emerging clinical data suggest that interventions targeting muscle physiology directly may play an important role in supporting women undergoing metabolic change
A 2025 JAMA Psychiatry trial (Hendershot et al.) tested lower-dose semaglutide over nine weeks and found reductions in some laboratory measures with smaller real-world effects, suggesting the higher 2.4 mg dose may matter
Effect in skin lightening varies from one person to another
Whilst a mild, asymptomatic rise in resting heart rate is generally considered an expected pharmacological effect of GLP-1-based therapies, certain presentations should prompt timely medical review
(PubMed) Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H